Kiniksa Pharmaceuticals International, plc Income (Loss) from Continuing Operations before Income Taxes, Domestic
Kiniksa Pharmaceuticals International, plc (KNSA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $2.77 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $2.77M.
- Kiniksa Pharmaceuticals International, plc income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$7.67M.
- Kiniksa Pharmaceuticals International, plc income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$91.13M.
- Kiniksa Pharmaceuticals International, plc income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$84.07M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $2.77M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$7.67M 10-K · filed 2026-02-24 |
| 2023-12-31 | -$91.13M 10-K · filed 2026-02-24 |
| 2022-12-31 | -$84.07M 10-K · filed 2025-02-25 |
| 2021-12-31 | -$164.28M 10-K · filed 2024-02-28 |
| 2020-12-31 | -$161.98M 10-K · filed 2023-03-02 |
| 2019-12-31 | -$168.05M 10-K · filed 2022-02-24 |
| 2018-12-31 | -$105.56M 10-K · filed 2021-02-25 |
| 2017-12-31 | -$65.39M 10-K · filed 2019-03-12 |